These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 38251405)
1. The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review. Le KDR; Le K; Foo F Pharmacy (Basel); 2024 Jan; 12(1):. PubMed ID: 38251405 [TBL] [Abstract][Full Text] [Related]
2. Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI). Sprung VS; Kemp GJ; Wilding JP; Adams V; Murphy K; Burgess M; Emegbo S; Thomas M; Needham AJ; Weimken A; Schwab RJ; Manuel A; Craig SE; Cuthbertson DJ BMJ Open; 2020 Jul; 10(7):e038856. PubMed ID: 32699168 [TBL] [Abstract][Full Text] [Related]
3. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Mason M; Cates CJ; Smith I Cochrane Database Syst Rev; 2015 Jul; (7):CD011090. PubMed ID: 26171909 [TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory medications for obstructive sleep apnoea in children. Kuhle S; Hoffmann DU; Mitra S; Urschitz MS Cochrane Database Syst Rev; 2020 Jan; 1(1):CD007074. PubMed ID: 31978261 [TBL] [Abstract][Full Text] [Related]
5. The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome. Sultana R; Sissoho F; Kaushik VP; Raji MA Life (Basel); 2022 Aug; 12(8):. PubMed ID: 36013401 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757 [TBL] [Abstract][Full Text] [Related]
8. Drug therapy for obstructive sleep apnoea in adults. Mason M; Welsh EJ; Smith I Cochrane Database Syst Rev; 2013 May; (5):CD003002. PubMed ID: 23728641 [TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Hemmingsen B; Sonne DP; Metzendorf MI; Richter B Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review. Xie Z; Hu J; Gu H; Li M; Chen J Front Endocrinol (Lausanne); 2023; 14():1244432. PubMed ID: 37701904 [TBL] [Abstract][Full Text] [Related]
12. The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. Liu Y; Ruan B; Jiang H; Le S; Liu Y; Ao X; Huang Y; Shi X; Xue R; Fu X; Wang S Am J Clin Nutr; 2023 Sep; 118(3):614-626. PubMed ID: 37661106 [TBL] [Abstract][Full Text] [Related]
13. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Seufert J; Gallwitz B Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150 [TBL] [Abstract][Full Text] [Related]
14. Drug therapy for obstructive sleep apnoea in adults. Smith I; Lasserson TJ; Wright J Cochrane Database Syst Rev; 2006 Apr; (2):CD003002. PubMed ID: 16625567 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Pinelli NR; Hurren KM Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278 [TBL] [Abstract][Full Text] [Related]
19. Non-invasive positive pressure ventilation for central sleep apnoea in adults. Pinto ACPN; Rocha A; Pachito DV; Drager LF; Lorenzi-Filho G Cochrane Database Syst Rev; 2022 Oct; 10(10):CD012889. PubMed ID: 36278514 [TBL] [Abstract][Full Text] [Related]
20. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus. Tsukamoto S; Tanaka S; Yamada T; Uneda K; Azushima K; Kinguchi S; Wakui H; Tamura K Diabetes Obes Metab; 2024 Jan; 26(1):262-274. PubMed ID: 37828829 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]